Scientech Research LLC’s Axsome Therapeutics AXSM Stock Holding History

Scientech Research LLC’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,593	Closed	-$656K	–	482
2025 Q4	$656K	Buy	+3,593	New	+$502K	0.41%	53
2025 Q2	–	Sell	-9,759	Closed	-$1.14M	–	597
2025 Q1	$1.14M	Buy	+9,759	New	+$1.11M	0.3%	62

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scientech Research LLC's AXSM Position: Q1 2026 in Review

Scientech Research LLC sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 3,593 shares — an estimated $656K sold.

Scientech Research LLC first reported a position in AXSM in Q1 2025 and held it in 2 quarters. The position peaked at $1.14M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Scientech Research LLC reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Scientech Research LLC sold 3,593 Axsome Therapeutics shares in Q1 2026, an estimated $656K.
Scientech Research LLC first reported a position in Axsome Therapeutics in Q1 2025 and held it in 2 quarters.
Scientech Research LLC's Axsome Therapeutics position peaked at $1.14M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.